TABLE 2.
Baseline levels of CSF biomarkers, cognitive tests, and vascular factors
| A+T+N+ | A+T‐N‐ | A‐T+N+ | A‐T+N‐ | A‐T‐N+ | A‐T‐N‐ | |
|---|---|---|---|---|---|---|
| N | 97 (23) | 34 (8) | 87 (20) | 34 (8) | 24 (6) | 137 (33) |
| CSF markers: | ||||||
| Aβ42, (ng/L) | 365 ± 74 | 382 ± 84 | 751 ± 197 | 750 ± 133 | 763 ± 228 | 707 ± 150 |
| P‐tau (ng/L) | 89 ± 32 | 35 ± 8 | 71 ± 18 | 69 ± 40 | 46 ± 4 | 38 ± 7 |
| T‐tau (ng/L) | 676 ± 354 | 192 ± 64 | 519 ± 202 | 267 ± 57 | 365 ± 50 | 208 ± 59 |
| Neuropsychological tests: | ||||||
| RAVLT DR | 4.5 ± 4.0** | 7.2 ± 3.2* | 6.8 ± 3.6* | 8.6 ± 3.2 | 7.3 ± 4.7 | 8.9 ± 3.4 |
| TMT A | 49 ± 20* | 41 ± 15 | 43 ± 15 | 38 ± 16 | 49 ± 18 | 37 ± 13 |
| TMT B | 133 ± 69* | 108 ± 57 | 104 ± 48 | 82 ± 27 | 111 ± 60 | 90 ± 44 |
| WAIS digit span | 12.8 ± 3 | 13.4 ± 4 | 12.9 ± 4 | 13.4 ± 3 | 12.3 ± 3 | 13.6 ± 3 |
| RCF recall | 9.0 ± 7** | 13.3 ± 7* | 14.1 ± 7 | 18.5 ± 7 | 14.5 ± 7 | 17.4 ± 7 |
| RCF copy | 30 ± 6* | 32 ± 4 | 32 ± 5 | 33 ± 3 | 30 ± 6* | 32 ± 3 |
| F‐A‐S test | 38 ± 12 | 37 ± 15 | 39 ± 13 | 41 ± 14 | 35 ± 11 | 43 ± 13 |
| VOSP silhouettes | 19 ± 5* | 20 ± 4 | 20 ± 4 | 22 ± 4 | 20 ± 5 | 21 ± 4 |
| Stroop | 36 ± 17* | 33 ± 17 | 31 ± 9 | 28 ± 8 | 33 ± 11 | 28 ± 10 |
| Vascular factors: | ||||||
| WMC (cm3) | 3.6±3.5* | 8.3±8.9 | 4.4±5.0* | 4.3±3.0 | 4.8±4.0 | 6.7±6.9 |
| Vascular burden (%) | 31 | 30 | 26 | 31 | 35 | 28 |
Data are presented as the mean ± SD. ATN groups were compared to the A‐T‐N‐ group.
F‐A‐S test, Word fluency F‐A‐S test; RAVLT DR, Rey Auditory Verbal Learning Test Delayed Recall; RCF, Rey Complex Figure copy and recall; Stroop, Stroop Test Victoria version; TMT, Trail Making Test; Vascular burden, percentage of study participants with at least two vascular risk factors and not insignificant WMC; VOSP silhouettes, Visual Object and Space Perception Silhouettes subtest; WAIS, Wechsler Adult Intelligence Scale digit span; WMC volume, white matter changes volume.
*
P‐value <.05 versus A‐T‐N‐.
**
P‐value <.001 versus A‐T‐N‐.